Latest Synergies News

Titanium Sands has completed the environmental fieldwork and technical studies needed to submit its Mannar Heavy Mineral Project assessment in Sri Lanka. But the ASX-listed explorer ended September with just $61,000 in cash, a fully drawn $1.8 million loan facility and estimated funding for only 0.21 quarters.

LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.

I Synergy ended the September quarter with A$44,000 in cash and an estimated 0.76 quarters of funding, before securing A$200,000 in loan funding after quarter-end. Its proposed Macau digital economy partnership remains non-binding, while a prior half-year review flagged material uncertainty around going concern.

Narryer Metals is nearing completion of its Redhill Copper Project acquisition in Chile, adding an existing inferred resource and a much larger conceptual exploration target. The deal is backed by a proposed A$1 million placement from 29Metals, but Narryer ended the quarter with only A$927,000 in available cash.

GenusPlus has completed its acquisition of New Zealand telecommunications contractor UCG, extending the group’s communications infrastructure footprint into New Zealand and the Pacific Islands. The upfront consideration was funded from existing cash reserves and a debt facility, but the company has not disclosed the purchase price or expected earnings contribution.

Strickland Metals has ended the September quarter with a 9.25Moz AuEq resource at its Rogozna project, new geophysical targets in Serbia and A$75.7 million in cash and liquid investments. The next test is execution: drilling did not begin, licence approvals remain pending and a new managing director is yet to be appointed.

Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.

Count has reported a strong start to FY2027, with first-quarter revenue up 23.2%, underlying EBITA up 66.6% and funds under management reaching $6.7 billion. The group is also pursuing a 30% stake in Brisbane accounting and advice firm Apiary, although the purchase price remains undisclosed and completion requires ACCC approval.

Integral Diagnostics has opened FY27 below expectations, with radiologist and sonographer shortages limiting revenue growth and pushing labour costs ahead of sales. The company expects FY27 revenue growth of 4% to 6% and a full-year operating EBITDA margin of 19.5% to 20.5%, with improvement weighted to the second half.

Alcidion has started FY27 with contracted revenue up 38% to $50.0 million, while a major UK expansion and new patient administration product widen its growth case. The company has also reaffirmed that FY27 revenue and underlying EBITDA will exceed FY26, but its capital plan now has several competing demands.

Biotron’s BIT-HBV001 produced up to a 99.7% reduction in HBV-DNA in cell-based studies, while combination testing with Myrcludex B showed antiviral synergy. The company is also refining SedRx’s European regulatory pathway, but had A$1.06 million in cash at quarter-end, equivalent to 2.15 quarters of funding at the latest operating burn rate.

IVE Group’s FY26 revenue slipped 1.8%, but stronger margins lifted underlying pre-AASB 16 NPAT by 3.0% to A$52.5 million and supported a higher final dividend. The marketing and communications group expects underlying pre-AASB 16 profit to be broadly stable in FY27 as new capacity and acquisitions begin to contribute.